Page last updated: 2024-09-03

marimastat and Astrocytoma, Grade IV

marimastat has been researched along with Astrocytoma, Grade IV in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baillet, M; Forsyth, PA; Fuller, GN; Levin, VA; Maestro, RD; Perry, JR; Phuphanich, S; Yung, WK	1
Groves, MD; Hess, KR; Jaeckle, KA; Levin, VA; Peterson, P; Puduvalli, VK; Yung, WK	1

Trials

2 trial(s) available for marimastat and Astrocytoma, Grade IV

Article	Year
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. Journal of neuro-oncology, 2006, Volume: 78, Issue:3 Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Double-Blind Method; Enzyme Inhibitors; Female; Glioblastoma; Gliosarcoma; Humans; Hydroxamic Acids; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Musculoskeletal Diseases; Quality of Life; Survival Analysis; Treatment Failure	2006
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide	2002

Article

Year

Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation.

Journal of neuro-oncology, 2006, Volume: 78, Issue:3

Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Double-Blind Method; Enzyme Inhibitors; Female; Glioblastoma; Gliosarcoma; Humans; Hydroxamic Acids; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Musculoskeletal Diseases; Quality of Life; Survival Analysis; Treatment Failure

2006

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide

2002